Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

This study has been terminated.
(Novartis is ending their research program for Nilotinib in GIST.)
Information provided by (Responsible Party):
Fox Chase Cancer Center Identifier:
First received: January 28, 2010
Last updated: January 25, 2017
Last verified: January 2017
Results First Received: May 7, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Conditions: GIST
Metastatic Disease
Interventions: Drug: Nilotinib
Drug: Nilotinib with Imatinib

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
During the period of February 2, 2009 through May 26, 2011, recruitment occur at oncology hospital.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Nilotinib Nilotinib 400 mg po bid
Nilotinib + Imatinib Nilotinib 400 mg BID with Imatinib 400 mg daily

Participant Flow:   Overall Study
    Nilotinib   Nilotinib + Imatinib
STARTED   2   3 
COMPLETED   2   3 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Nilotinib Nilotinib 400 mg po bid
Nilotinib + Imatinib Nilotinib 400 mg BID with Imatinib 400 mg daily
Total Total of all reporting groups

Baseline Measures
   Nilotinib   Nilotinib + Imatinib   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   3   5 
[Units: Participants]
Count of Participants
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      1  50.0%      2  66.7%      3  60.0% 
>=65 years      1  50.0%      1  33.3%      2  40.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      1  50.0%      1  33.3%      2  40.0% 
Male      1  50.0%      2  66.7%      3  60.0% 
Region of Enrollment 
[Units: Participants]
United States   2   3   5 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression Free Survival   [ Time Frame: 6 months until death or for 5 years ]

2.  Secondary:   Best Overall Response Using Response Evaluation Criteria in Solid Tumors, Choi Criteria, and Positron Emission Tomography Imaging   [ Time Frame: Every 8 weeks for up to 5 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Trial ended early due to industry support of provision of nilotinib was discontinued.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Margaret von Mehren, Principal Investigator
Organization: Fox Chase Cancer Center
phone: 215-728-4300

Responsible Party: Fox Chase Cancer Center Identifier: NCT01089595     History of Changes
Other Study ID Numbers: FER-SAR-023
Study First Received: January 28, 2010
Results First Received: May 7, 2013
Last Updated: January 25, 2017